Key result
In a propensity score-matched analysis of patients with advanced HFrEF and diabetes, metformin treatment was associated with significantly better event-free survival (p=0.01) compared to other glucose-lowering therapies.
Why the study?
The role of metformin in the treatment of patients with advanced HFrEF and type 2 diabetes mellitus is not firmly established.
Does metformin improve survival and quality of life in patients with advanced HFrEF and type 2 diabetes mellitus compared to other glucose-lowering agents?
Population
380 patients with advanced HFrEF and DM from a cohort of 847 stable advanced HFrEF patients
Comparison
Metformin vs other glucose-lowering agents
Design
Prospective cohort study with propensity score-matched analysis
Follow-up
Median of 1126 days
Authors
Loading...
Metformin was associated with better survival in advanced HFrEF with diabetes; hypothesis-generating and requires randomized confirmation before practice change.
Cohort (n=847)
No
Does metformin improve survival and quality of life in patients with advanced HFrEF and type 2 diabetes mellitus compared to other glucose-lowering agents?
p-value: p=0.01
Metformin use in patients with advanced HFrEF and diabetes is associated with improved survival and quality of life compared to other glucose-lowering agents.
Beneš et al. (2022) conducted a cohort in Advanced heart failure with reduced ejection fraction (HFrEF) and type 2 diabetes mellitus (n=847). Metformin vs. Other glucose-lowering agents (metformin-free) was evaluated on Combined endpoint of death, urgent heart transplantation, or mechanical circulatory support implantation (p=0.01). In a propensity score-matched analysis of patients with advanced HFrEF and diabetes, metformin treatment was associated with significantly better event-free survival (p=0.01) compared to other glucose-lowering therapies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: